Recent Updates
Recently added Catalysts

LY2969822

Phase 1

Undisclosed | Small molecule | Other |Eli Lilly and Company|Trials Updated: Feb 21, 2019

LY2969822 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Dec 2013

LY2969822 target and mechanism

Molecular targetGRM2, GRM3
Target classAgonist
ModalitySmall molecule
ChEMBLCHEMBL3545270

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment99

FDA Designations

No designations recorded

LY2969822 clinical trials

LY2969822 · 1 trial · 1 indication

Phase 1 1
NCT02018887A Study of LY2969822 in Healthy ParticipantsHealthy Volunteers
COMPLETED99 Analytics
PHASE1COMPLETED
A Study of LY2969822 in Healthy Participants
Healthy Volunteers
NCT0201888799
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants With One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Baseline Through End of Study (up to Week 7)

A summary of other nonserious adverse events (AEs) and all SAEs, regardless of causality, is located in the Reported Adverse Events section.

Secondary Endpoints

Pharmacokinetics (PK): Maximum Plasma Concentration (Plasma Cmax) of Prodrug LY2969822 and Active Metabolite LSN2934747
All Cohorts: Day 1 - 0 Hours (H), 0.5 H, 1 H, 2 H, 3 H, 4 H, 6 H, 9 H, 12 H, 16 H; Cohort 3: Day 10 - 0 H, 0.5 H, 1 H, 2 H, 3 H, 4 H, 6 H, 9 H, 12 H, 16 H; Cohorts 3 - 8: Day 14 - 0 H, 0.5 H,1 H, 2 H, 3 H, 4 H, 6 H, 9 H, 12 H, 16 H
PK: Maximum Cerebrospinal Fluid Concentrations (CSF Cmax) of Prodrug LY2969822 and Active Metabolite LSN2934747
Cohort 8: Day 14 - 0 H, 0.5 H,1 H, 2 H, 3 H, 4 H, 6 H, 9 H, 12 H, 16 H
PK: Area Under the Drug Plasma Concentration Time Curve (Plasma AUC) of Prodrug LY2969822 and Active Metabolite LSN2934747
All Cohorts: Day 1 - 0 Hours (H), 0.5 H, 1 H, 2 H, 3 H, 4 H, 6 H, 9 H, 12 H, 16 H; Cohort 3: Day 10 - 0 H, 0.5 H, 1 H, 2 H, 3 H, 4 H, 6 H, 9 H, 12 H, 16 H; Cohorts 3 - 8: Day 14 - 0 H, 0.5 H,1 H, 2 H, 3 H, 4 H, 6 H, 9 H, 12 H, 16 H
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelCROSSOVER
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
LY2969822 (Part A)EXPERIMENTALSingle dose of LY2969822 administered orally in 2 of 3 study periods.
Placebo (Part A)PLACEBO_COMPARATORSingle dose of placebo administered orally in 1 of 3 study periods.
LY2969822 (Part B)EXPERIMENTALLY2969822 administered orally for 14 days.
Placebo (Part B)PLACEBO_COMPARATORPlacebo administered orally for 14 days.
LY2969822 (Part C)EXPERIMENTALLY2969822 administered orally for 14 days.
Placebo (Part C)PLACEBO_COMPARATORPlacebo administered orally for 14 days.

Interventions

NameTypeDescription
LY2969822DRUGCapsules administered orally
PlaceboDRUGCapsules administered orally
Unlock Study Design Details

Eligibility Criteria

Age Range21 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Male participants must agree to use a reliable method of birth control in addition to having their partner use another method for the duration of the study and for 3 months after the last dose of LY2969822 * Female participants must not be of child-bearing potential * Particip...

Countries:Singapore
Unlock Eligibility Criteria

Frequently asked questions about LY2969822

What is LY2969822?

LY2969822 is an investigational small molecule developed by Eli Lilly and Company. It is a Phase 1 clinical-stage compound that has been studied in healthy volunteers. No approved indication has been disclosed for LY2969822.

What does LY2969822 target?

LY2969822 targets the metabotropic glutamate receptors GRM2 and GRM3, also known as mGlu2 and mGlu3. It acts as an agonist at these receptors. This mechanism is being explored in early-stage clinical research.

Who makes LY2969822?

LY2969822 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the clinical program for this compound.

What phase is LY2969822 in?

LY2969822 is in Phase 1 clinical development. It has not been approved by the FDA or any other regulatory agency. The compound remains investigational and is not available as a marketed treatment.

What clinical trials is LY2969822 in?

LY2969822 has been evaluated in one completed Phase 1 trial, NCT02018887, titled A Study of LY2969822 in Healthy Participants. The trial enrolled 99 participants in Singapore and was randomized, double-blind, and placebo-controlled.

Other drugs targeting GRM2

JNJ-40411813 JNJ· PHASE2 LY2979165 LLY· PHASE1

Explore more on BiopharmaWatch

Eli Lilly and Company (LLY)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with LCompanies A to ZEvery biotech and pharma company we track